TheraRadar
Clinical-Stage Companies / Viking

Viking

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 6/23/2025

9
Total Trials
2
Phase 3
5
Phase 2
2
Recruiting
76
Score

Pipeline by Phase

Phase 3
2
Phase 2
5
Phase 1
2

Therapeutic Focus

Weight Loss Hip Fractures Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) NASH NASH - Nonalcoholic Steatohepatitis

Clinical Trials (9)

NCT07104383 Phase 3 ACTIVE NOT RECRUITING

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Started: 6/23/2025

NCT07104500 Phase 3 ACTIVE NOT RECRUITING

VK2735 for Weight Management Phase 3

Started: 6/23/2025

NCT02578095 Phase 2 COMPLETED

Acute Hip Fracture Study in Patients 65 Years or Greater

Started: 10/30/2015

NCT06828055 Phase 2 COMPLETED

VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

Started: 12/18/2024

NCT06068946 Phase 2 COMPLETED

VK2735 for Weight Management Phase 2

Started: 8/31/2023

NCT04173065 Phase 2 COMPLETED

A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH

Started: 11/15/2019

NCT02927184 Phase 2 COMPLETED

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

Started: 9/28/2016

NCT04973657 Phase 1 COMPLETED

A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN

Started: 6/22/2021

NCT05203237 Phase 1 COMPLETED

Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

Started: 12/14/2021

Drug Candidates

VK2735 VK5211 VK0214 VK2735 Drug VK2809
Activity Status: Slowing
Last Trial Started: 6/23/2025
Last Trial Ended: 8/15/2025
Trials (12 months): 0
Completed Trials: 7
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.